REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Form 10-Q — Aug 12, 2026
Reviva Pharmaceuticals issued a going-concern warning in its Q2 2026 10-Q, disclosing that its $19.9 million of cash is not sufficient to satisfy operating cash needs for the 12 months from the filing date and that conditions raise substantial doubt about its ability to continue as a going concern. Management believes cash covers anticipated outlays into July 2027 but states additional fundraising is required, with no guarantees or commitments in place.
Key figures
- Total Debt
- 144093
- Total Assets
- 21140590
- Cash Position
- 19889960
- Shares Outstanding
- 13110377
- Accumulated deficit
- 189781770
- Reverse split ratio
- 1:20
- Atm program capacity
- 50000000
- Cash runway estimate
- into July 2027
- R and d expense q2 2025
- 3724755
- R and d expense q2 2026
- 1394569
- Working capital surplus
- 15207245
- Nasdaq form 25 filing date
- 2026-07-10
- Warrants outstanding shares
- 17479474
- Nasdaq trading suspension date
- 2026-05-14
- Shares outstanding dec 31 2025
- 5872865
- Atm net proceeds six months 2026
- 2500000
- March 2026 offering net proceeds
- 8900000
- Total operating expenses q2 2026
- 2617543
- March 2026 offering gross proceeds
- 10000000
- March 2026 offering price per share
- 1.5
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.